SAB Biotherapeutics Announces Departure of Chief Financial Officer

May 30, 2024

https://www.globenewswire.com/news-release/2024/05/30/2891175/0/en/SAB-Biotherapeutics-Announces-Departure-of-Chief-Financial-Officer.html

MIAMI, May 30, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq:SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of T1D, today announced that effective June 4, its Chief Financial Officer Michael King will be departing the company to accept a role as CEO at a privately-held oncology company. He will continue as an advisor to SAB through the end of the year.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.